Global Romiplostim Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Romiplostim Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Romiplostim, sold under the brand name Nplate among others, is a fusion protein analog of thrombopoietin, a hormone that regulates platelet production. Romiplostim injection is used to treat low blood platelet counts (thrombocytopenia) and help prevent bleeding in patients with a blood disorder called immune thrombocytopenia (ITP).
Romiplostim Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Romiplostim Injection market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Adults and Pediatric Patients are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Romiplostim Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Romiplostim Injection key manufacturers include Amgen, Kyowa Kirin and Intas Pharmaceuticals, etc. Amgen, Kyowa Kirin, Intas Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Romiplostim Injection can be divided into 250 μg/0.5 mL and 500 μg/1 mL, etc. 250 μg/0.5 mL is the mainstream product in the market, accounting for % sales share globally in 2022.
Romiplostim Injection is widely used in various fields, such as Adults and Pediatric Patients, etc. Adults provides greatest supports to the Romiplostim Injection industry development. In 2022, global % sales of Romiplostim Injection went into Adults filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Romiplostim Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Kyowa Kirin
Intas Pharmaceuticals
Segment by Type
250 μg/0.5 mL
500 μg/1 mL
Adults
Pediatric Patients
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Romiplostim Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Romiplostim Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Romiplostim Injection industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Romiplostim Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Romiplostim Injection introduction, etc. Romiplostim Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Romiplostim Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Romiplostim Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Romiplostim Injection market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Adults and Pediatric Patients are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Romiplostim Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Romiplostim Injection key manufacturers include Amgen, Kyowa Kirin and Intas Pharmaceuticals, etc. Amgen, Kyowa Kirin, Intas Pharmaceuticals are top 3 players and held % sales share in total in 2022.
Romiplostim Injection can be divided into 250 μg/0.5 mL and 500 μg/1 mL, etc. 250 μg/0.5 mL is the mainstream product in the market, accounting for % sales share globally in 2022.
Romiplostim Injection is widely used in various fields, such as Adults and Pediatric Patients, etc. Adults provides greatest supports to the Romiplostim Injection industry development. In 2022, global % sales of Romiplostim Injection went into Adults filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Romiplostim Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Kyowa Kirin
Intas Pharmaceuticals
Segment by Type
250 μg/0.5 mL
500 μg/1 mL
Segment by Application
Adults
Pediatric Patients
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Romiplostim Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Romiplostim Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Romiplostim Injection industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Romiplostim Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Romiplostim Injection introduction, etc. Romiplostim Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Romiplostim Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices